THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.

被引：0
作者：
Xin, Y. [1 ]
Collins, H. [1 ]
Cheng, F. [1 ]
Kwan, E. [1 ]
Ramanathan, S. [1 ]
Silverman, J. A. [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-049
引用
收藏
页码：S87 / S88
页数：2
相关论文
共 50 条
[31]   Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects [J].
Flanagan, Shawn ;
Ong, Voon ;
Marbury, Thomas ;
Jandourek, Alena ;
Gandhi, Ronak G. ;
Sandison, Taylor .
PHARMACOTHERAPY, 2024, 44 (06) :435-443
[32]   Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment [J].
Li, Yan ;
MacGorman, Kimberly ;
Liu, Liangang ;
Chen, Jian ;
Hoffmann, Matthew ;
Palmisano, Maria ;
Zhou, Simon .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07) :785-796
[33]   Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment [J].
Custodio, Joseph M. ;
Fordyce, Marshall ;
Garner, William ;
Vimal, Mona ;
Ling, Kah Hiing J. ;
Kearney, Brian P. ;
Ramanathan, Srinivasan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) :5135-5140
[34]   Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment [J].
Yang, Haijing ;
Zhang, Min ;
Chen, Yuancheng ;
Ren, Hong ;
Zhang, Hong ;
Yu, Chen ;
Lu, Jianda ;
You, Li ;
Yu, Jicheng ;
Liang, Hong ;
Xiao, Cuilan ;
He, Zishuang ;
Wu, Jufang ;
Xue, Jun ;
Zhang, Jing .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (07) :1079-1086
[35]   Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment [J].
Haijing Yang ;
Min Zhang ;
Yuancheng Chen ;
Hong Ren ;
Hong Zhang ;
Chen Yu ;
Jianda Lu ;
Li You ;
Jicheng Yu ;
Hong Liang ;
Cuilan Xiao ;
Zishuang He ;
Jufang Wu ;
Jun Xue ;
Jing Zhang .
European Journal of Clinical Pharmacology, 2022, 78 :1079-1086
[36]   Pharmacokinetics (PK) of garenoxacin in healthy subjects and in subjects with hepatic impairment. [J].
Noveck, RJ ;
Vargas, R ;
Russo, R ;
Bello, A ;
Gajjar, D ;
Grasela, D .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) :P79-P79
[37]   Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment. [J].
Akce, Mehmet ;
El-Khoueiry, Anthony B. ;
Piha-Paul, Sarina Anne ;
Bacque, Emeline ;
Pan, Peng ;
Zhang, Zhi-Yi ;
Ewesuedo, Reginald ;
Gupta, Divya ;
Milton, Ashley ;
Judson, Patricia ;
O'Bryant, Cindy L. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[38]   The pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran in patients with severe renal impairment. [J].
Eriksson, UG ;
Samuelsson, O ;
Attman, PO ;
Mulec, H ;
Johausson, S ;
Frison, L ;
Fager, G .
BLOOD, 2001, 98 (11) :268A-268A
[39]   The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment [J].
Nichols, A. I. ;
Richards, L. S. ;
Behrle, J. A. ;
Posener, J. A. ;
McGrory, S. B. ;
Paul, J. .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (01) :3-13
[40]   Pharmacokinetics of eslicarbazepine acetate in patients with moderate liver impairment. [J].
Maia, Joana ;
Potgieter, J. Henk ;
Almeida, Luis ;
Soares-da-Silva, P. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09) :1192-1192
12345